Comparative Effectiveness of Symbicort vs. Advair Among COPD Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

3000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2013-08-31

Study Completion Date

2014-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is intended to evaluate treatment effectiveness of BFC compared to FSC in COPD patients new to ICS/LABA combination therapy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Symbicort in Chronic Obstruktive Pulmonary Disease

NCT00612976

Pulmonary Disease, Chronic Obstructive

COMPLETED

Symbicort in Chronic Obstructive Pulmonary Disease

NCT00611520

Chronic Obstructive Pulmonary Disease

COMPLETED

A Study to Investigate the Differential Effects of Inhaled Symbicort and Advair on Lung Microbiota

NCT02833480

Chronic Obstructive Pulmonary Disease

UNKNOWN PHASE2

A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and 2 x 80/4.5 μg Bid With Formoterol Turbuhaler® 2 x 4.5 μg Bid and Placebo in Patients With COPD

NCT00206167

Chronic Obstructive Pulmonary Disease

COMPLETED PHASE3

Symbicort in Airway Predominant Chronic Obstructive Pulmonary Disease (COPD)

NCT01253473

Pulmonary Disease, Chronic Obstructive

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COPD

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Symbicort

BFC patients new to ICS/LABA therapies

No interventions assigned to this group

Advair

FSC patients new to ICS/LABA therapies.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Continuous health plan enrollment for 12 months before and after index Rx, at least one prescription for BFC or FSC during intake period, naive to ICS/LABA therapies in year prior to first prescription claim, COPD diagnosis, aged 40 or over at time of first prescription.

Exclusion Criteria

* ICS/LABA combination during pre-index period, patients with a claim for BFC and FSC on the same day, patients diagnosed with cancer, patients with long-term OCS medication use during pre-index period.

Minimum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No